[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"taxane-induced-peripheral-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:taxane-induced-peripheral-neuropathy":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100597923","cryocompression-for-cipn-100597923",false,"NCT07064798","Cryocompression for CIPN","Evaluating the Use of Limb Cryocompression to Reduce Taxane-induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults \\> 18 years of age\n* Gynecologic or breast malignancy\n* Starting 1st cycle of treatment with chemotherapy regimens:\n\n  * Weekly paclitaxel x 12 or weekly paclitaxel\u002Fcarboplatin x 12, Q2 weeks paclitaxel X4 (preceded by doxorubicin\u002Fcyclophosphamide). (Breast Oncology)\n  * Q3 weeks paclitaxel\u002Fcarboplatin X 6-8 (GYN)\n* Receiving treatment on the main campus of DFCI (these patients are currently seen on Yawkey 9 and 10 and at Chestnut Hill)\n* Able to complete questionnaires in English or Spanish\n\nExclusion Criteria:\n\n* Previous exposure to neurotoxic chemotherapy\n* Pre-existing neuropathy\n* History of Raynaud's phenomenon, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, post-traumatic cold dystrophy, peripheral arterial ischemia, or sickle cell disease\n* Undergoing desensitization\n* Lymphedema in the limb where the device would be applied\n* Open skin wounds or ulcers of the limbs where the device would be applied","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effectiveness, tolerability, and safety of using cooling therapy and pressure (cryocompression) to reduce peripheral neuropathy, a condition affecting the nerves supplying the arms and legs (limbs) resulting in possible numbness, pain, and\u002For loss of motor function, that may occur as a result of taxane-based chemotherapy.\n\nThe name of the device used in this research study is:\n\n-Paxman Limb Cryocompression System (PLCS)",[26,27,28],"Chemotherapy-induced Peripheral Neuropathy","Taxane-Induced Peripheral Neuropathy","CIPN - Chemotherapy-Induced Peripheral Neuropathy",[30,26,27,31],"Peripheral Neuropathy","CIPN","RECRUITING","2026-04-14",{"date":35,"type":36},"2026-04-15","ACTUAL",{"date":38,"type":36},"2025-10-22",{"date":40,"type":20},"2027-08",{"name":42,"class":43},"Dana-Farber Cancer Institute","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100632275","prospective-exploratory-study-of-a-multiomic-blood-biomarker-panel-to-predict-chemotherapy-induced-peripheral-neuropathy-cipn-100632275","NCT07511569","Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)","PRECISE1","Inclusion Criteria:\n\n* Patients who have received detailed information about the study and have signed, with the investigator, a consent form to participate in the study\n* Patients being treated for cancer at any stage of the disease and scheduled to receive chemotherapy including one (and only one) of the following molecules: paclitaxel, docetaxel, or oxaliplatin, for a planned duration of 9 weeks or more\n* Age \\> 18 years\n* Life expectancy \\> 3 months\n* Patient affiliated with or entitled to social security\n\nExclusion Criteria:\n\n* Patients already suffering from neuropathy or chronic neurogenic pain\n* Patients with type 1 or type 2 diabetes (for more than 10 years for type 2 diabetes)\n* Patients who have already received neurotoxic cancer treatment including those in clinical trials\n* Patients receiving two of the study molecules simultaneously (only one study molecule is permitted, including in combination chemotherapy but that does not include another neurotoxic molecule)\n* Patients receiving immunotherapy",{"count":53,"type":20},192,"OBSERVATIONAL","The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.",[57,58,59,60],"Chemotherapy Induced Neuropathic Pain","Neuropathy Toxic","Taxane-induced Peripheral Neuropathy","Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients","NOT_YET_RECRUITING","2026-04-07",{"date":64,"type":36},"2026-04-13",{"date":66,"type":20},"2027-01-04",{"date":68,"type":20},"2029-06-04",{"name":70,"class":43},"Centre Hospitalier de Bligny",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":44},"100551780","evaluation-of-the-efficacy-of-compression-with-tight-surgical-gloves-in-patients-with-taxane-based-therapy-100551780","NCT06464536","Evaluation of the Efficacy of Compression With Tight Surgical Gloves in Patients With Taxane-based Therapy","Tight Surgical Gloves to Prevent Chemotherapy-induced Peripheral Neuropathy: A Randomized Controlled Trial to Evaluate the Efficacy of Compression Therapy in Patients With Taxane-based Chemotherapy for Breast and Urogenital Cancer","ComPrendo","Inclusion Criteria:\n\n* Mamma or Urogenital carcinoma\n* first treatment with Taxanes (nab-Paclitaxel, Paclitaxel, Docetaxel)\n* signed informed consent\n* sufficient proficiency in German or English\n\nExclusion Criteria:\n\n* other therapy that could have caused peripheral neuropathy within the last 24 months (Taxane, Platin, Vincaalkaloids, etc.)\n* History of neuropathy such as Raynaud's phenomenon, fibromyalgia and diabetic polyneuropathy\n* Use of polyneuropathy medications including duloxetine; gabapentin\u002Fpregabalin; topical amitriptyline, ketamine, baclofen; oral cannabinoids; tricyclic antidepressants; and ganglioside monosialic acid\n* such impaired cognition that prevents participation in the study according to the assessment of the caregivers",{"count":80,"type":20},114,[23],"In this study, the effect of compression therapy of the hands with tight surgical gloves to reduce peripheral neuropathy in adult patients during the application of taxanes will be evaluated.",[59],"2025-05-13",{"date":86,"type":36},"2025-05-16",{"date":88,"type":36},"2025-02-03",{"date":90,"type":20},"2026-03",{"name":92,"class":43},"St.Gallen University of Applied Sciences"]